Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AN4035 + unspecified EGFR tyrosine kinase inhibitor |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AN4035 | AN-4035|AN 4035 | CEACAM5 Antibody 14 RAS Inhibitor (Pan) 16 | Limited information is currently available on AN4035, a putative antibody-drug conjugate (ADC) comprising an antibody targeting CEACAM5 linked to a pan-RAS(ON) inhibitor (Jul 2026). | |
| unspecified EGFR tyrosine kinase inhibitor | EGFR Inhibitor (Pan) 63 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07686445 | Phase I | AN4035 + unspecified EGFR tyrosine kinase inhibitor AN4035 | A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression | Not yet recruiting | AUS | 0 |